Scientific Advisory Board
Julie Glowacki, Ph.D. Professor, Harvard University School of Medicine
Dr. Glowacki is a Professor in the Department of Orthopedic Surgery, School of Medicine, and a Professor in the Department of Oral/Maxillofacial Surgery at the School of Dental Medicine at Harvard University. The author of over 100 articles and multiple textbooks and book chapters, Dr. Glowacki’s research examines the function of engineered joints, the molecular mechanisms by which demineralized bone initiates cartilage formation, and the mechanisms by which steroids (androgens) increase bone mass in young patients with accelerated bone loss due to anorexia nervosa.
John Lowe, M.D. Professor, Case Western Reserve University School of Medicine
Dr. Lowe is the Henry Wilson Payne Professor and Chair of the Department of Pathology at Case Western Reserve University School of Medicine, and an Adjunct Professor at the Burnham Institute in La Jolla, CA. A recognized expert in protein modifications, Dr. Lowe has founded two biotechnology companies and served on their boards. His current research addresses the molecular control of glycosylation events in inflammation and disease. He has authored over 120 research articles, chapters and books.
W. Stratford May, M.D., Ph.D. Professor, University of Florida Shands Cancer Center
Dr. May is the Harry F. Innes Professor in Cancer Research at The University of Florida. He is also the Director of the University of Florida Shands Cancer Center and a Professor in the Departments of Medicine, Biochemistry & Molecular Biology, and Pharmacology & Therapeutics at the University of Florida School of Medicine. The author of over 90 research publications and numerous chapters, reviews, and books, Dr. May is an expert in the area of cellular signaling. His current research examines cell signaling pathways. Dr. May is also the director of the Shands Cancer Center training grant that trains physicians and scientists at the post-doctoral level.
Mary R. Flack, M.D., Vice President of Clinical & Regulatory Affairs, NanoBio, Inc.
Dr. Flack has nearly 20 years of clinical research experience at the NIH and in the pharmaceutical industry. Before joining NanoBio in 2002, Dr. Flack was Clinical Director of Endocrinology and Women's Health Care at Pfizer (formerly Parke-Davis/Warner-Lambert) where she was responsible for clinical development of pharmaceutical products for osteoporosis, hormone replacement therapy, fertility and contraception. She directed the completion of multiple clinical studies (Phases I-IV), leading to four approved NDA submissions, and has extensive experience with three different divisions of the FDA, including dermatology, endocrinology and reproductive health.
